In today’s ACT Brief, we examine who decides what trials measure, how designing for human thinking improves site execution, and how the FDA extended an immunotherapy to a new bladder cancer population.
News|Podcasts|November 26, 2025
ACT Brief: AI in Clinical Research, FDA Gene Therapy Approval, and High-Performing Hospital Partnerships
Author(s)Andy Studna, Senior Editor
In today’s ACT Brief, we examine how AI is being integrated into administrative workflows at investigative sites, highlight the FDA’s approval of the first gene therapy for adolescents and adults with SMA, and explore strategies for pharmaceutical companies to build high-performing hospital-based clinical trial programs.
This is the Applied Clinical Trials Brief—your fast track to the latest insights in clinical research operations. In under three minutes, we’ll recap top stories, highlight expert perspectives, and keep you current on what’s moving the industry.
- A new feature
article from Norman Goldfarb explores how AI agents, AI teammates, and integrated intelligence are poised to reshape site-level operations in clinical research. Administrative workflows—including site closeout, document review, and task tracking—are prime candidates for partial or full automation, while humans retain responsibility for judgment-intensive and relationship-driven tasks. Investigative sites that leverage AI effectively may reduce timelines, improve consistency, and lower operational costs, offering more value to sponsors and freeing study staff to focus on higher-value clinical work. - The FDA has
approved Itvisma, the first gene replacement therapy for adolescents, teens, and adults with spinal muscular atrophy (SMA) who carry SMN1 mutations. Approval was based on Phase III STEER and Phase IIIb STRENGTH studies demonstrating motor function improvements and a favorable safety profile. This milestone expands access to gene therapy for a broader SMA population and signals opportunities for clinical operations teams to engage adult neurology and community practice sites in upcoming late-stage and post-marketing trials. - Another new feature
article highlights strategies for pharmaceutical companies to partner effectively with hospitals to grow clinical trial programs. By addressing operational, financial, and organizational barriers—such as long start-up timelines, high staff turnover, and misaligned research support—pharma can work with hospital leadership to implement enterprise-wide improvements. Case studies, including Henry Ford Health, show that structured partnerships, executive engagement, and optimized research infrastructure can accelerate accrual, expand study capacity, and strengthen hospital-based clinical research operations.
That’s all for today’s ACT Brief. Join us next week for more updates shaping clinical operations and drug development. Thanks for listening.
Related to this article
In Episode 3 of The Human Side of Clinical Trials, hosts Brian S. McGowan, PhD, FACEHP, chief learning officer and co-founder of ArcheMedX, Inc., and Kelly Ritch, chief operating officer of ArcheMedX, Inc., speak with Jason Riis, PhD, CEO and chief behavioral scientist at Behavioralize, about why a well-written protocol doesn’t always translate into consistent execution, and how designing for the way people actually think and learn can reduce site burden and the need for costly unlearning.
In today’s ACT Brief, we examine what it will take to scale EHR-to-EDC connections for real-time trials, how the FDA is reimagining rare disease drug development, and why oncology real-world evidence still faces persistent data barriers.
In today's ACT Brief, we examine how representation gaps in trials are shaped by structural design decisions, how new partnerships automate data transfer from site systems to sponsor platforms, and how Roche is licensing a novel obesity target from a biotech pioneer.
Trialbee CEO Matt Walz explores the current impact of AI in delivering practical gains in clinical development and reflects on its future potential, where enrollment predictability may be the biggest prize of all.
In today's ACT Brief, we examine proportionate analysis frequency in RBQM, how to build trust into real-world evidence foundations for cancer trials, and how rare disease developers monetize regulatory success.
In today's ACT Brief, we examine how AI surfaces design flaws before enrollment, why site training readiness depends on learning science, and the priorities defining next-generation weight-loss therapies.
In today's ACT Brief, we examine the FDA's multi-domain transparency priorities, why radiopharmaceutical trials need redesigned infrastructure, and how AI can make enrollment more predictable.
Trending on Applied Clinical Trials Online
1
Real-Time Clinical Trials Depend on a Scalable EHR-to-EDC Connection
2
FDA Launches Rare Disease Framework Initiative to Reimagine Drug Development for Small Patient Populations
3
The Human Side of Clinical Trials: Why Fuzzy Mental Models Undermine Clinical Trial Execution
4
Endpoints That Reflect What Patients Actually Value: Who Decides What Counts as Trial Success
5